Full Press Release Details
dupixent dupilumab sbla accepted for fda review for the treatment of chronic spontaneous urticaria csu.
REGN
dupixent dupilumab sbla accepted for fda review for the treatment of chronic spontaneous urticaria csu
Key Takeaway: dupixent dupilumab sbla accepted for fda review for the treatment of chronic spontaneous urticaria csu